Company intelligence / Profile preview
Cellestia Biotech
Basel, Switzerlandcellestia.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Lead compound CB-103 has demonstrated safety and biological activity in humans. It is currently in Phase 2 clinical trials for multi-drug resistant cancers and poised to enter a Proof-of-Concept clinical study for graft-versus-host disease (GvHD)[9]. CB-103 has shown efficacy in animal models for GvHD prophylaxis[9].
- Therapeutic areas
- OncologyImmunology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Cellestia Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cellestia Biotech.